Zahlen für Q3/22
-projected runway into 2025
https://cardiffoncology.investorroom.com/...Provides-Business-Updates
Zahlen für Q2/23
- to fund its operations into 2025
https://cardiffoncology.investorroom.com/...-Provides-Business-Update
Zahlen für Q3/23
- Expanded relationship with Pfizer, which will provide clinical execution of new Phase 2 randomized first-line mCRC trial of onvansertib + standard-of-care (SoC) versus SoC, with interim topline data expected in mid-2024